Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial by Hutson, Thomas E, Prof, Lesovoy, Vladimir, Prof, Al-Shukri, Salman, Prof, Stus, Viktor P, Prof, Lipatov, Oleg N, Prof, Bair, Angel H, PhD, Rosbrook, Brad, MS, Chen, Connie, PharmD, Kim, Sinil, MD, Vogelzang, Nicholas J, Prof

Get full text

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled p... by Paz-Ares, Luis, Dr, Mezger, Jörg, Prof, Ciuleanu, Tudor E, Prof, Fischer, Jürgen R, MD, von Pawel, Joachim, MD, Provencio, Mariano, Prof, Kazarnowicz, Andrzej, MD, Losonczy, György, Prof, de Castro, Gilberto, MD, Szczesna, Aleksandra, MD, Crino, Lucio, MD, Reck, Martin, MD, Ramlau, Rodryg, Prof, Ulsperger, Ernst, MD, Schumann, Christian, MD, Miziara, Jose Elias A, MD, Lessa, Álvaro E, MD, Dediu, Mircea, MD, Bálint, Beatrix, PhD, Depenbrock, Henrik, MD, Soldatenkova, Victoria, MSc, Kurek, Raffael, MD, Hirsch, Fred R, Prof, Thatcher, Nick, FRCP, Socinski, Mark A, Prof

Get full text